{"id":21245,"date":"2026-10-27T08:58:08","date_gmt":"2026-10-27T08:58:08","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/?post_type=case-study&#038;p=21245"},"modified":"2026-10-27T08:58:09","modified_gmt":"2026-10-27T08:58:09","slug":"overcoming-complex-cytotoxic-chemistry-discovery-to-clinic-in-14-months","status":"publish","type":"case-study","link":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/overcoming-complex-cytotoxic-chemistry-discovery-to-clinic-in-14-months\/","title":{"rendered":"Overcoming Complex Cytotoxic Chemistry: Discovery to Clinic in 14 Months"},"content":{"rendered":"\n<h2 class=\"wp-block-heading has-text-2-xl-font-size\">Overcoming Complex Cytotoxic Chemistry<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Developing tumor-selective cytotoxic therapies requires the seamless integration of expertise across chemistry, biology, DMPK and analytical sciences. <strong>Avacta Therapeutics<\/strong> partnered with Sygnature Discovery to advance its FAP-activated peptide-drug conjugate program, with the goal of selectively delivering potent cytotoxic therapies to tumors while minimizing systemic toxicity.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Through close collaboration, integrated discovery expertise and rapid iteration, our teams overcame complex scientific and technical challenges to accelerate candidate progression. By combining innovative assay development, computational chemistry and multidisciplinary drug discovery capabilities, Sygnature supported the delivery of <strong>AVA6103<\/strong>, progressing the program from discovery to clinical candidate nomination in just 14 months. Along the way, the collaboration generated valuable platform insights, expanded intellectual property opportunities and demonstrated the power of connected discovery in advancing complex oncology programs.<\/p>\n\n\n\n<div class=\"wp-block-group alignfull is-style-default has-ivory-000-color has-text-color has-background is-layout-flow wp-block-group-is-layout-flow\" style=\"border-radius:1.5em;background:linear-gradient(90deg,rgb(0,60,97) 0%,rgb(4,30,46) 100%);margin-top:var(--wp--preset--spacing--40);margin-bottom:var(--wp--preset--spacing--40);padding-right:var(--wp--preset--spacing--50);padding-left:var(--wp--preset--spacing--50)\" allowchildrentofillwidth=\"\" overflow=\"\" flexwrap=\"\">\n<div style=\"height:64px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center has-small-font-size wp-block-paragraph\" style=\"line-height:.9\"><strong>CASE STUDY<\/strong><\/p>\n\n\n\n<h4 class=\"wp-block-heading has-text-align-center has-text-xl-font-size\" id=\"schedule-a-visit\" style=\"line-height:1.15\">See the complete project timeline, scientific insight and multidisciplinary approach that accelerated this program.<\/h4>\n\n\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-dd0a6548 wp-block-buttons-is-layout-flex\">\n<div style=\"--wp--block-button--width: 50;\" class=\"wp-block-button has-custom-width wp-block-button__width wp-block-button__width-50\" modaltype=\"\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/10\/Avacta_Overcoming-Complex-Cytotoxic-Chemistry.pdf\">Download<\/a><\/div>\n<\/div>\n\n\n\n<div style=\"height:64px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading has-text-xl-font-size\">About Avacta Therapeutics<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Avacta Therapeutics is a clinical-stage biotechnology company developing precision oncology medicines through its proprietary pre|CISION\u00ae platform. Designed to selectively activate highly potent therapies within the tumour microenvironment, the platform aims to maximize anti-tumour efficacy while reducing systemic toxicity. Through its pipeline of targeted therapeutics, Avacta is advancing novel approaches intended to improve outcomes for patients with cancer.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h3 class=\"wp-block-heading has-text-xl-font-size\">About Sygnature Discovery<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Sygnature Discovery is a world-leading integrated drug discovery contract research organization with sites in the UK and Canada and headquarters in Nottingham (UK), serving biotech and pharma customers across the United States, Canada, the United Kingdom and Europe. Additional sites are located in Alderley Park, Macclesfield, and Glasgow (UK), as well as Montreal and Quebec City (Canada). Its team of close to 900 employees, including 700+ scientists, partners with global biotech, pharma and NFP organizations. Since 2011, Sygnature has delivered 61 novel pre-clinical compounds, 38 of which have already progressed to clinical trials. Two have reached major milestones: one has been approved, and another is under regulatory review. Our scientists are named on more than 235 patents and our therapeutic areas of expertise span oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases, and more.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Advancing AVA6103 from discovery to clinical candidate nomination in just 14 months<\/p>\n","protected":false},"featured_media":21249,"template":"","category":[],"resource_tag":[],"class_list":["post-21245","case-study","type-case-study","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FAP-Activated Peptide-Drug Conjugates | AVA6103 Case Study<\/title>\n<meta name=\"description\" content=\"FAP-activated peptide-drug conjugates delivered AVA6103 from discovery to clinical nomination in 14 months, with 200+ PDCs synthesised and 400+ compounds screened.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/overcoming-complex-cytotoxic-chemistry-discovery-to-clinic-in-14-months\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FAP-Activated Peptide-Drug Conjugates | AVA6103 Case Study\" \/>\n<meta property=\"og:description\" content=\"FAP-activated peptide-drug conjugates delivered AVA6103 from discovery to clinical nomination in 14 months, with 200+ PDCs synthesised and 400+ compounds screened.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/overcoming-complex-cytotoxic-chemistry-discovery-to-clinic-in-14-months\/\" \/>\n<meta property=\"og:site_name\" content=\"Sygnature\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-27T08:58:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/10\/Avacta-Case-Study-Feature-Image.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1001\" \/>\n\t<meta property=\"og:image:height\" content=\"588\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/overcoming-complex-cytotoxic-chemistry-discovery-to-clinic-in-14-months\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/overcoming-complex-cytotoxic-chemistry-discovery-to-clinic-in-14-months\\\/\",\"name\":\"FAP-Activated Peptide-Drug Conjugates | AVA6103 Case Study\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/overcoming-complex-cytotoxic-chemistry-discovery-to-clinic-in-14-months\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/overcoming-complex-cytotoxic-chemistry-discovery-to-clinic-in-14-months\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Avacta-Case-Study-Feature-Image.webp\",\"datePublished\":\"2026-10-27T08:58:08+00:00\",\"dateModified\":\"2026-10-27T08:58:09+00:00\",\"description\":\"FAP-activated peptide-drug conjugates delivered AVA6103 from discovery to clinical nomination in 14 months, with 200+ PDCs synthesised and 400+ compounds screened.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/overcoming-complex-cytotoxic-chemistry-discovery-to-clinic-in-14-months\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/overcoming-complex-cytotoxic-chemistry-discovery-to-clinic-in-14-months\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/overcoming-complex-cytotoxic-chemistry-discovery-to-clinic-in-14-months\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Avacta-Case-Study-Feature-Image.webp\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Avacta-Case-Study-Feature-Image.webp\",\"width\":1001,\"height\":588},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/overcoming-complex-cytotoxic-chemistry-discovery-to-clinic-in-14-months\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Overcoming Complex Cytotoxic Chemistry: Discovery to Clinic in 14 Months\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"name\":\"Sygnature Discovery\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"alternateName\":\"Sygnature\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\",\"name\":\"Sygnature Discovery\",\"alternateName\":\"Sygnature\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Sygnature Discovery\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.youtube.com\\\/@sygnature.discovery\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/sygnature-discovery\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FAP-Activated Peptide-Drug Conjugates | AVA6103 Case Study","description":"FAP-activated peptide-drug conjugates delivered AVA6103 from discovery to clinical nomination in 14 months, with 200+ PDCs synthesised and 400+ compounds screened.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/overcoming-complex-cytotoxic-chemistry-discovery-to-clinic-in-14-months\/","og_locale":"fr_CA","og_type":"article","og_title":"FAP-Activated Peptide-Drug Conjugates | AVA6103 Case Study","og_description":"FAP-activated peptide-drug conjugates delivered AVA6103 from discovery to clinical nomination in 14 months, with 200+ PDCs synthesised and 400+ compounds screened.","og_url":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/overcoming-complex-cytotoxic-chemistry-discovery-to-clinic-in-14-months\/","og_site_name":"Sygnature","article_modified_time":"2026-10-27T08:58:09+00:00","og_image":[{"width":1001,"height":588,"url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/10\/Avacta-Case-Study-Feature-Image.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/overcoming-complex-cytotoxic-chemistry-discovery-to-clinic-in-14-months\/","url":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/overcoming-complex-cytotoxic-chemistry-discovery-to-clinic-in-14-months\/","name":"FAP-Activated Peptide-Drug Conjugates | AVA6103 Case Study","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/overcoming-complex-cytotoxic-chemistry-discovery-to-clinic-in-14-months\/#primaryimage"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/overcoming-complex-cytotoxic-chemistry-discovery-to-clinic-in-14-months\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/10\/Avacta-Case-Study-Feature-Image.webp","datePublished":"2026-10-27T08:58:08+00:00","dateModified":"2026-10-27T08:58:09+00:00","description":"FAP-activated peptide-drug conjugates delivered AVA6103 from discovery to clinical nomination in 14 months, with 200+ PDCs synthesised and 400+ compounds screened.","breadcrumb":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/overcoming-complex-cytotoxic-chemistry-discovery-to-clinic-in-14-months\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/overcoming-complex-cytotoxic-chemistry-discovery-to-clinic-in-14-months\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/overcoming-complex-cytotoxic-chemistry-discovery-to-clinic-in-14-months\/#primaryimage","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/10\/Avacta-Case-Study-Feature-Image.webp","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/10\/Avacta-Case-Study-Feature-Image.webp","width":1001,"height":588},{"@type":"BreadcrumbList","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/overcoming-complex-cytotoxic-chemistry-discovery-to-clinic-in-14-months\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sygnaturediscovery.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Overcoming Complex Cytotoxic Chemistry: Discovery to Clinic in 14 Months"}]},{"@type":"WebSite","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","name":"Sygnature Discovery","description":"","publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"alternateName":"Sygnature","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sygnaturediscovery.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization","name":"Sygnature Discovery","alternateName":"Sygnature","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","width":1,"height":1,"caption":"Sygnature Discovery"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.youtube.com\/@sygnature.discovery","https:\/\/www.linkedin.com\/company\/sygnature-discovery\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/case-study\/21245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/case-study"}],"about":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/types\/case-study"}],"version-history":[{"count":4,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/case-study\/21245\/revisions"}],"predecessor-version":[{"id":21251,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/case-study\/21245\/revisions\/21251"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media\/21249"}],"wp:attachment":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media?parent=21245"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/category?post=21245"},{"taxonomy":"resource_tag","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/resource_tag?post=21245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}